Brouwer & Janachowski LLC boosted its stake in shares of Johnson & Johnson (NYSE:JNJ) by 34.0% in the 2nd quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 3,093 shares of the company’s stock after acquiring an additional 784 shares during the quarter. Brouwer & Janachowski LLC’s holdings in Johnson & Johnson were worth $409,000 as of its most recent filing with the Securities and Exchange Commission (SEC).
A number of other hedge funds also recently modified their holdings of JNJ. Lau Associates LLC lifted its holdings in Johnson & Johnson by 12.8% in the 1st quarter. Lau Associates LLC now owns 46,878 shares of the company’s stock worth $5,839,000 after buying an additional 5,335 shares during the period. Jackson Grant Investment Advisers Inc. lifted its holdings in Johnson & Johnson by 7.3% in the 4th quarter. Jackson Grant Investment Advisers Inc. now owns 14,124 shares of the company’s stock worth $1,627,000 after buying an additional 957 shares during the period. Burke & Herbert Bank & Trust Co. lifted its holdings in Johnson & Johnson by 2.6% in the 1st quarter. Burke & Herbert Bank & Trust Co. now owns 47,330 shares of the company’s stock worth $5,895,000 after buying an additional 1,218 shares during the period. Lynch & Associates IN lifted its holdings in Johnson & Johnson by 0.9% in the 2nd quarter. Lynch & Associates IN now owns 93,710 shares of the company’s stock worth $12,397,000 after buying an additional 841 shares during the period. Finally, Paradigm Financial Advisors LLC lifted its holdings in Johnson & Johnson by 17.1% in the 1st quarter. Paradigm Financial Advisors LLC now owns 2,640 shares of the company’s stock worth $328,000 after buying an additional 386 shares during the period. Institutional investors own 66.00% of the company’s stock.
Johnson & Johnson (NYSE JNJ) traded down 0.83% during midday trading on Tuesday, reaching $132.10. The company’s stock had a trading volume of 2,814,292 shares. The stock’s 50 day moving average price is $132.39 and its 200-day moving average price is $128.93. The stock has a market cap of $354.56 billion, a price-to-earnings ratio of 22.35 and a beta of 0.79. Johnson & Johnson has a one year low of $109.32 and a one year high of $137.08.
Johnson & Johnson (NYSE:JNJ) last posted its quarterly earnings results on Tuesday, July 18th. The company reported $1.83 EPS for the quarter, beating the consensus estimate of $1.79 by $0.04. Johnson & Johnson had a net margin of 22.52% and a return on equity of 26.76%. The company had revenue of $18.84 billion for the quarter, compared to analyst estimates of $18.94 billion. During the same period in the prior year, the company earned $1.74 earnings per share. The firm’s revenue was up 1.9% on a year-over-year basis. On average, analysts forecast that Johnson & Johnson will post $7.18 EPS for the current fiscal year.
The company also recently announced a quarterly dividend, which will be paid on Tuesday, September 12th. Stockholders of record on Tuesday, August 29th will be paid a dividend of $0.84 per share. This represents a $3.36 annualized dividend and a dividend yield of 2.52%. The ex-dividend date of this dividend is Friday, August 25th. Johnson & Johnson’s payout ratio is currently 56.76%.
In other news, VP Dominic J. Caruso sold 82,591 shares of the stock in a transaction dated Thursday, July 20th. The shares were sold at an average price of $136.72, for a total transaction of $11,291,841.52. Following the sale, the vice president now directly owns 226,693 shares of the company’s stock, valued at approximately $30,993,466.96. The transaction was disclosed in a filing with the SEC, which is available at this hyperlink. Also, VP Paulus Stoffels sold 102,692 shares of the stock in a transaction dated Monday, July 24th. The stock was sold at an average price of $133.14, for a total transaction of $13,672,412.88. Following the sale, the vice president now directly owns 230,342 shares in the company, valued at $30,667,733.88. The disclosure for this sale can be found here. Corporate insiders own 0.19% of the company’s stock.
Several research analysts have recently issued reports on the company. BidaskClub raised Johnson & Johnson from a “buy” rating to a “strong-buy” rating in a research report on Saturday, June 17th. Royal Bank Of Canada reissued a “buy” rating and issued a $128.00 target price on shares of Johnson & Johnson in a research report on Thursday, June 15th. Atlantic Securities lowered Johnson & Johnson from a “neutral” rating to an “underweight” rating and set a $113.00 target price for the company. in a research report on Friday, July 21st. Jefferies Group LLC reissued a “hold” rating and issued a $145.00 target price (up previously from $140.00) on shares of Johnson & Johnson in a research report on Friday, July 14th. Finally, Morgan Stanley raised their price objective on Johnson & Johnson from $135.00 to $140.00 and gave the company an “overweight” rating in a research report on Wednesday, July 5th. Three investment analysts have rated the stock with a sell rating, nine have issued a hold rating and nine have given a buy rating to the company’s stock. The stock currently has a consensus rating of “Hold” and a consensus price target of $134.60.
ILLEGAL ACTIVITY WARNING: “Brouwer & Janachowski LLC Has $409,000 Position in Johnson & Johnson (JNJ)” was originally posted by Ticker Report and is owned by of Ticker Report. If you are viewing this report on another publication, it was stolen and republished in violation of U.S. and international trademark & copyright laws. The correct version of this report can be read at https://www.tickerreport.com/banking-finance/2886989/brouwer-janachowski-llc-has-409000-position-in-johnson-johnson-jnj.html.
Johnson & Johnson Profile
Johnson & Johnson is a holding company, which is engaged in the research and development, manufacture and sale of a range of products in the healthcare field. It operates through three segments: Consumer, Pharmaceutical and Medical Devices. Its primary focus is products related to human health and well-being.
Want to see what other hedge funds are holding JNJ? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Johnson & Johnson (NYSE:JNJ).
Receive News & Ratings for Johnson & Johnson Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Johnson & Johnson and related companies with MarketBeat.com's FREE daily email newsletter.